US8226941B2 - Methods of purifying chondroitinase and stable formulations thereof - Google Patents
Methods of purifying chondroitinase and stable formulations thereof Download PDFInfo
- Publication number
- US8226941B2 US8226941B2 US11/568,831 US56883105A US8226941B2 US 8226941 B2 US8226941 B2 US 8226941B2 US 56883105 A US56883105 A US 56883105A US 8226941 B2 US8226941 B2 US 8226941B2
- Authority
- US
- United States
- Prior art keywords
- chondroitinase
- activity
- cabci
- formulation
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 108010023736 Chondroitinases and Chondroitin Lyases Proteins 0.000 title claims abstract description 165
- 102000011413 Chondroitinases and Chondroitin Lyases Human genes 0.000 title claims abstract description 163
- 239000000203 mixture Substances 0.000 title claims abstract description 54
- 238000009472 formulation Methods 0.000 title claims abstract description 45
- 238000000034 method Methods 0.000 title abstract description 53
- 102000004190 Enzymes Human genes 0.000 claims abstract description 66
- 108090000790 Enzymes Proteins 0.000 claims abstract description 66
- 230000000694 effects Effects 0.000 claims description 107
- 101710106625 Chondroitinase-AC Proteins 0.000 claims description 28
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 13
- 239000001632 sodium acetate Substances 0.000 claims description 13
- 235000017281 sodium acetate Nutrition 0.000 claims description 13
- 108010048429 chondroitinase B Proteins 0.000 claims description 8
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 7
- 102100039283 Hyaluronidase-1 Human genes 0.000 claims description 5
- 102100039285 Hyaluronidase-2 Human genes 0.000 claims description 5
- 102100021082 Hyaluronidase-3 Human genes 0.000 claims description 5
- 102100021081 Hyaluronidase-4 Human genes 0.000 claims description 5
- 101710199677 Hyaluronidase-4 Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 101150056481 HYAL1 gene Proteins 0.000 claims description 4
- 101150001550 HYAL2 gene Proteins 0.000 claims description 4
- 101150065827 HYAL3 gene Proteins 0.000 claims description 4
- 102100021102 Hyaluronidase PH-20 Human genes 0.000 claims 2
- 101150055528 SPAM1 gene Proteins 0.000 claims 2
- 101000910471 Proteus vulgaris Chondroitin sulfate ABC endolyase Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 abstract description 22
- 239000000284 extract Substances 0.000 abstract description 20
- 238000005277 cation exchange chromatography Methods 0.000 abstract description 14
- 238000001641 gel filtration chromatography Methods 0.000 abstract description 8
- 239000003011 anion exchange membrane Substances 0.000 abstract description 6
- 239000012535 impurity Substances 0.000 abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 56
- 239000000872 buffer Substances 0.000 description 55
- 210000004027 cell Anatomy 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 44
- 102000004169 proteins and genes Human genes 0.000 description 43
- 235000018102 proteins Nutrition 0.000 description 42
- 229920002567 Chondroitin Polymers 0.000 description 32
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical class CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 31
- 239000004094 surface-active agent Substances 0.000 description 30
- 239000011780 sodium chloride Substances 0.000 description 28
- 239000000523 sample Substances 0.000 description 25
- 238000000746 purification Methods 0.000 description 22
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 21
- 108090000765 processed proteins & peptides Proteins 0.000 description 20
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 19
- 229910052938 sodium sulfate Inorganic materials 0.000 description 19
- 239000013598 vector Substances 0.000 description 19
- -1 cationic lipid Chemical class 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 17
- 102000004196 processed proteins & peptides Human genes 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 239000000758 substrate Substances 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 16
- 238000002523 gelfiltration Methods 0.000 description 15
- 238000011534 incubation Methods 0.000 description 15
- 239000001488 sodium phosphate Substances 0.000 description 15
- 229910000162 sodium phosphate Inorganic materials 0.000 description 15
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 15
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 13
- 210000003169 central nervous system Anatomy 0.000 description 12
- 230000006378 damage Effects 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 239000011734 sodium Substances 0.000 description 12
- 238000000527 sonication Methods 0.000 description 12
- 208000027418 Wounds and injury Diseases 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 208000014674 injury Diseases 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 238000001542 size-exclusion chromatography Methods 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 229920002683 Glycosaminoglycan Polymers 0.000 description 10
- 210000000278 spinal cord Anatomy 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 239000012506 Sephacryl® Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 208000020431 spinal cord injury Diseases 0.000 description 9
- 229920001287 Chondroitin sulfate Polymers 0.000 description 8
- 229910019142 PO4 Inorganic materials 0.000 description 8
- 229930006000 Sucrose Natural products 0.000 description 8
- 239000007983 Tris buffer Substances 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000002779 inactivation Effects 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 229910052751 metal Inorganic materials 0.000 description 8
- 239000002184 metal Substances 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 8
- 239000010452 phosphate Substances 0.000 description 8
- 230000000717 retained effect Effects 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 239000005720 sucrose Substances 0.000 description 8
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 8
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 7
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 7
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000008033 biological extinction Effects 0.000 description 7
- 238000005341 cation exchange Methods 0.000 description 7
- 150000001768 cations Chemical class 0.000 description 7
- 229940059329 chondroitin sulfate Drugs 0.000 description 7
- 238000000502 dialysis Methods 0.000 description 7
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 7
- 229910000397 disodium phosphate Inorganic materials 0.000 description 7
- 210000003527 eukaryotic cell Anatomy 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002093 isoelectric focusing polyacrylamide gel electrophoresis Methods 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 6
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 6
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 229920004929 Triton X-114 Polymers 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 238000005571 anion exchange chromatography Methods 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000037424 autonomic function Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000007659 motor function Effects 0.000 description 5
- 210000002241 neurite Anatomy 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010257 thawing Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 208000034656 Contusions Diseases 0.000 description 4
- 229920000045 Dermatan sulfate Polymers 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 206010061431 Glial scar Diseases 0.000 description 4
- 206010018341 Gliosis Diseases 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 238000005349 anion exchange Methods 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000007857 degradation product Substances 0.000 description 4
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 4
- 229940051593 dermatan sulfate Drugs 0.000 description 4
- 239000003599 detergent Substances 0.000 description 4
- 150000002016 disaccharides Chemical group 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229920000136 polysorbate Polymers 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940124272 protein stabilizer Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000037152 sensory function Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000012536 storage buffer Substances 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 238000003260 vortexing Methods 0.000 description 4
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 3
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 3
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 3
- 239000001099 ammonium carbonate Substances 0.000 description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 3
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 3
- 235000011130 ammonium sulphate Nutrition 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000006555 catalytic reaction Methods 0.000 description 3
- 239000003729 cation exchange resin Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000009519 contusion Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000011013 endotoxin removal Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000005374 membrane filtration Methods 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000000944 nerve tissue Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 229920002113 octoxynol Polymers 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000001428 peripheral nervous system Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000002731 protein assay Methods 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 229910052709 silver Inorganic materials 0.000 description 3
- 239000004332 silver Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- HORQAOAYAYGIBM-UHFFFAOYSA-N 2,4-dinitrophenylhydrazine Chemical compound NNC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O HORQAOAYAYGIBM-UHFFFAOYSA-N 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 239000007989 BIS-Tris Propane buffer Substances 0.000 description 2
- 241000701822 Bovine papillomavirus Species 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 241000588767 Proteus vulgaris Species 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- AEMOLEFTQBMNLQ-UHFFFAOYSA-N beta-D-galactopyranuronic acid Natural products OC1OC(C(O)=O)C(O)C(O)C1O AEMOLEFTQBMNLQ-UHFFFAOYSA-N 0.000 description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 229940023913 cation exchange resins Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108010072542 endotoxin binding proteins Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 210000003709 heart valve Anatomy 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- MSQACBWWAIBWIC-UHFFFAOYSA-N hydron;piperazine;chloride Chemical compound Cl.C1CNCCN1 MSQACBWWAIBWIC-UHFFFAOYSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000013541 low molecular weight contaminant Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 230000007514 neuronal growth Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- MFMLMKLBWODGNA-UHFFFAOYSA-N propane-1,3-diamine;hydrochloride Chemical compound Cl.NCCCN MFMLMKLBWODGNA-UHFFFAOYSA-N 0.000 description 2
- 229940007042 proteus vulgaris Drugs 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000012496 stress study Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000012784 weak cation exchange Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- IOFMNTLYVBEPDH-JEDNCBNOSA-N (2S)-2-amino-3-(1H-imidazol-5-yl)propanoic acid formic acid Chemical compound N[C@@H](CC1=CNC=N1)C(=O)O.C(=O)O IOFMNTLYVBEPDH-JEDNCBNOSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- OEANUJAFZLQYOD-CXAZCLJRSA-N (2r,3s,4r,5r,6r)-6-[(2r,3r,4r,5r,6r)-5-acetamido-3-hydroxy-2-(hydroxymethyl)-6-methoxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](OC)O[C@H](CO)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](OC)[C@H](C(O)=O)O1 OEANUJAFZLQYOD-CXAZCLJRSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- PMUNIMVZCACZBB-UHFFFAOYSA-N 2-hydroxyethylazanium;chloride Chemical compound Cl.NCCO PMUNIMVZCACZBB-UHFFFAOYSA-N 0.000 description 1
- OQUFOZNPBIIJTN-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium Chemical compound [Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OQUFOZNPBIIJTN-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- BYMMIQCVDHHYGG-UHFFFAOYSA-N Cl.OP(O)(O)=O Chemical compound Cl.OP(O)(O)=O BYMMIQCVDHHYGG-UHFFFAOYSA-N 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 101100084900 Drosophila melanogaster Rpn11 gene Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 101710199679 Hyaluronidase-1 Proteins 0.000 description 1
- 101710199674 Hyaluronidase-2 Proteins 0.000 description 1
- 108050004076 Hyaluronidase-3 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 125000000899 L-alpha-glutamyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- AEMOLEFTQBMNLQ-HNFCZKTMSA-N L-idopyranuronic acid Chemical compound OC1O[C@@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-HNFCZKTMSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 102100023206 Neuromodulin Human genes 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- 206010067633 Peripheral nerve lesion Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- ZDPALFHDPFYJDY-UHFFFAOYSA-N [Na].OC=O Chemical compound [Na].OC=O ZDPALFHDPFYJDY-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940050528 albumin Drugs 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000012436 analytical size exclusion chromatography Methods 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000004507 artificial chromosome Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- CMPOVQUVPYXEBN-UHFFFAOYSA-N bis(2-hydroxyethyl)-methylazanium;chloride Chemical compound Cl.OCCN(C)CCO CMPOVQUVPYXEBN-UHFFFAOYSA-N 0.000 description 1
- VJLOFJZWUDZJBX-UHFFFAOYSA-N bis(2-hydroxyethyl)azanium;chloride Chemical compound [Cl-].OCC[NH2+]CCO VJLOFJZWUDZJBX-UHFFFAOYSA-N 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- VEIWYFRREFUNRC-UHFFFAOYSA-N hydron;piperidine;chloride Chemical compound [Cl-].C1CC[NH2+]CC1 VEIWYFRREFUNRC-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 238000012886 linear function Methods 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 229910001386 lithium phosphate Inorganic materials 0.000 description 1
- RDURKEQPWGIVCS-UHFFFAOYSA-N lithium;propanedioic acid Chemical compound [Li].OC(=O)CC(O)=O RDURKEQPWGIVCS-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000013021 overheating Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- ZYFGTJPGLOESBV-UHFFFAOYSA-N propanedioic acid;sodium Chemical compound [Na].OC(=O)CC(O)=O ZYFGTJPGLOESBV-UHFFFAOYSA-N 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- RDZTWEVXRGYCFV-UHFFFAOYSA-M sodium 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonate Chemical compound [Na+].OCCN1CCN(CCS([O-])(=O)=O)CC1 RDZTWEVXRGYCFV-UHFFFAOYSA-M 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000012607 strong cation exchange resin Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000004964 sulfoalkyl group Chemical group 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000004044 tetrasaccharides Chemical group 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- HHLJUSLZGFYWKW-UHFFFAOYSA-N triethanolamine hydrochloride Chemical compound Cl.OCCN(CCO)CCO HHLJUSLZGFYWKW-UHFFFAOYSA-N 0.000 description 1
- TWQULNDIKKJZPH-UHFFFAOYSA-K trilithium;phosphate Chemical compound [Li+].[Li+].[Li+].[O-]P([O-])([O-])=O TWQULNDIKKJZPH-UHFFFAOYSA-K 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000012608 weak cation exchange resin Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 101150061422 yip5 gene Proteins 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02004—Chondroitin ABC lyase (4.2.2.4), i.e. chondroitinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- FIG. 10 Dependence of cABCI thermal stability on ionic strength of in the presence of 50 mM Na Phosphate buffer.
- chondroitinase gene can be produced by ligating a nucleic acid encoding a chondroitinase protein, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Procedures for ligation are well known to those of ordinary skill in the art.
- Expression vectors for production of recombinant forms of the subject chondroitinase polypeptides include plasmids and other vectors.
- Gel filtration chromatography is a separation based on size. It is also called molecular exclusion or gel permeation chromatography.
- the stationary phase consists of porous beads with a well-defined range of pore sizes.
- the stationary phase for gel filtration is said to have a fractionation range, meaning that molecules within that molecular weight range can be separated.
- the final enzyme yield can be up to about 50 mg chondroitinase from 1 L cultured cells. In a further embodiment the final enzyme yield can be in the range of about 75 to 85 mg/l L of cells.
- a purified formulation of a chondroitinase a recombinant ABCI was purified and characterized using the methods of the present invention using the following parameters: temperature stability, enzyme characteristics, susceptibility to various stress conditions, degradation products; effects of different excipients on enzyme stability.
- the cells expressing chondroitinase AC were extracted using a square tip sonicator at a maximum speed of about 9. Sonication was performed for about 30 seconds. This was immediately followed by about 10 seconds with no sonication. These on/off steps were performed for a total of about 10 cycles. Each pellet was sonicated separately and then pooled. Extractions were rocked overnight at 4° C.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/568,831 US8226941B2 (en) | 2004-05-18 | 2005-05-18 | Methods of purifying chondroitinase and stable formulations thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57203004P | 2004-05-18 | 2004-05-18 | |
US62188204P | 2004-10-25 | 2004-10-25 | |
PCT/US2005/017464 WO2005112986A2 (en) | 2004-05-18 | 2005-05-18 | Purifying chondroitinase and stable formulations thereof |
US11/568,831 US8226941B2 (en) | 2004-05-18 | 2005-05-18 | Methods of purifying chondroitinase and stable formulations thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
US20080311642A1 US20080311642A1 (en) | 2008-12-18 |
US8226941B2 true US8226941B2 (en) | 2012-07-24 |
Family
ID=35428854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/568,831 Active 2027-12-25 US8226941B2 (en) | 2004-05-18 | 2005-05-18 | Methods of purifying chondroitinase and stable formulations thereof |
Country Status (8)
Country | Link |
---|---|
US (1) | US8226941B2 (es) |
EP (1) | EP1750757B1 (es) |
JP (1) | JP4926962B2 (es) |
AU (1) | AU2005244933B2 (es) |
CA (1) | CA2566731C (es) |
ES (1) | ES2411504T3 (es) |
MX (2) | MXPA06013345A (es) |
WO (1) | WO2005112986A2 (es) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9796970B1 (en) | 2017-04-24 | 2017-10-24 | Advantek Serum Laboratories Ltd. | Production of high purity chondroitinase ABC |
WO2018200290A1 (en) * | 2017-04-24 | 2018-11-01 | Advantek Serum Laboratories Ltd. | Production of high purity chondroitinase abc |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60336341D1 (de) | 2002-05-04 | 2011-04-21 | Acorda Therapeutics Inc | Zusammensetzungen und verfahren zur förderung des neuronalen wachstums |
AU2003243396A1 (en) | 2002-06-03 | 2003-12-19 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase b |
US7959914B2 (en) | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
MX348062B (es) | 2003-05-16 | 2017-05-26 | Acorda Therapeutics Inc | Mutantes que degradan proteoglicanos para tratamiento del snc. |
EP1928490B8 (en) | 2005-09-26 | 2012-10-03 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
ES2473610T3 (es) | 2006-10-10 | 2014-07-07 | Acorda Therapeutics, Inc. | Composiciones y métodos de uso de mutantes de condroitinasa ABCI |
JP2011136911A (ja) * | 2009-12-25 | 2011-07-14 | Tosoh Corp | 甲状腺刺激ホルモンレセプターの安定化方法 |
AU2013323679A1 (en) * | 2012-09-25 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Treatment of Central Nervous System (CNS) injury |
Citations (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01500308A (ja) | 1986-07-17 | 1989-02-02 | ヒユーズ・エアクラフト・カンパニー | 軌道上の回転体の姿勢の制御方法 |
WO1991006303A1 (en) | 1989-10-27 | 1991-05-16 | Case Western Reserve University | Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
US5270194A (en) * | 1989-08-31 | 1993-12-14 | Instrumentation Laboratory Spa | Stabilized glucose oxidase from Aspergillus Niger |
JPH06153947A (ja) | 1992-06-26 | 1994-06-03 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼabc、その製造法及び医薬組成物 |
WO1994025567A1 (en) | 1993-04-23 | 1994-11-10 | American Cyanamid Company | CLONING AND EXPRESSION OF THE CHONDROITINASE I AND II GENES FROM $i(P. VULGARIS) |
WO1995013091A1 (en) | 1993-11-12 | 1995-05-18 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
US5496718A (en) | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
US5498536A (en) | 1994-04-22 | 1996-03-12 | American Cyanamid Company | Chondroitinase II from Proteus vulgaris |
EP0704532A2 (en) | 1994-06-10 | 1996-04-03 | United States Surgical Corporation | Recombinant chimeric proteins and methods of use thereof |
US5578480A (en) | 1993-04-23 | 1996-11-26 | American Cyanamid Company | Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris |
US5652122A (en) | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
JPH10174598A (ja) | 1996-12-18 | 1998-06-30 | Nissho Corp | 生体成分測定用試薬の安定化方法 |
US5792743A (en) | 1995-04-19 | 1998-08-11 | Acorda Therapeutics | Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5869301A (en) | 1995-11-02 | 1999-02-09 | Lockhead Martin Energy Research Corporation | Method for the production of dicarboxylic acids |
WO1999040787A1 (en) | 1998-02-13 | 1999-08-19 | Medinox, Inc. | Modified pharmacologically active agents and improved therapeutic methods employing same |
JPH11236336A (ja) | 1997-05-02 | 1999-08-31 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物 |
WO1999046368A2 (en) | 1998-03-13 | 1999-09-16 | Biomarin Pharmaceuticals | Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment |
US5997863A (en) | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
US6007810A (en) | 1997-05-02 | 1999-12-28 | Seikagaku Corporation | Chondroitinase compositions |
US6063378A (en) | 1997-08-22 | 2000-05-16 | Seikagaku Corporation | Therapeutic agent for herniated intervertebral disc |
US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
WO2000052149A1 (en) | 1999-03-02 | 2000-09-08 | Insight Strategy & Marketing Ltd. | Introducing a biological material into a patient |
WO2000062067A1 (en) | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
WO2000064482A1 (en) | 1999-04-21 | 2000-11-02 | Karolinska Innovations Ab | Nerve cell growth modulators (amphibodies) |
US6153187A (en) | 1997-09-02 | 2000-11-28 | Insight Strategy & Marketing Ltd. | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
WO2000075319A1 (en) | 1999-06-08 | 2000-12-14 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
US6171575B1 (en) | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
US6200564B1 (en) | 1997-04-11 | 2001-03-13 | J. Thomas Lamont | Pharmaceutical compositions containing chondroitinase and uses therefor |
WO2001039795A2 (en) | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
US6313265B1 (en) | 1995-07-24 | 2001-11-06 | The Scripps Research Institute | Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use |
US6326166B1 (en) | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
WO2002008285A2 (en) | 2000-06-22 | 2002-01-31 | Amgen, Inc. | Il-17 molecules and uses thereof |
JP2002505873A (ja) | 1998-03-13 | 2002-02-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 血管内皮増殖因子2 |
WO2002055684A2 (en) | 2001-01-09 | 2002-07-18 | Univ Iowa Res Found | Synthetic proteins containing a protein transduction domain |
JP2002526028A (ja) | 1997-10-17 | 2002-08-20 | ジェネンテック・インコーポレーテッド | ヒトトール相同体 |
WO2002065136A2 (en) | 2001-02-15 | 2002-08-22 | University Of Chicago | Yeast screens for agents affecting protein folding |
WO2002083179A2 (en) | 2001-04-12 | 2002-10-24 | Bioaxone Therapeutique Inc. | Fusion proteins |
WO2003000901A2 (en) | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Nucleic acids encoding protein kinases |
JP2003500016A (ja) | 1999-04-02 | 2003-01-07 | イーライ・リリー・アンド・カンパニー | hOB−BP2h組成物、方法およびその使用 |
WO2003015612A2 (en) | 2001-08-13 | 2003-02-27 | University Of Florida Research Foundation, Inc. | Materials and methods to promote repair of nerve tissue |
WO2003022882A2 (en) | 2001-09-11 | 2003-03-20 | Procorde Gmbh | Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
WO2003031578A2 (en) | 2001-10-09 | 2003-04-17 | Immunex Corporation | Mammalian c-type lectins |
WO2003074080A1 (en) | 2002-03-04 | 2003-09-12 | Cambridge University Technical Services Limited | Treatment of central nervous system damage |
WO2003100031A2 (en) | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2003102160A2 (en) | 2002-06-03 | 2003-12-11 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase b |
US20040033221A1 (en) | 1998-10-06 | 2004-02-19 | Koichi Masuda | Method for the treatment of chemonucleolysis |
WO2004017044A2 (en) | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
JP2004089191A (ja) | 2002-08-09 | 2004-03-25 | Sysmex Corp | 脂質測定試薬 |
JP2004113166A (ja) | 2002-09-27 | 2004-04-15 | Mitsui Chemicals Inc | ハロペルオキシダ−ゼ活性の安定化方法 |
AU2004241088A1 (en) | 2003-05-16 | 2004-12-02 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of CNS injuries |
WO2004110359A2 (en) | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of cns |
WO2004110360A2 (en) | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
US20040265297A1 (en) | 2003-05-16 | 2004-12-30 | Gruskin Elliott A. | Methods of reducing extravasation of inflammatory cells |
WO2005087920A2 (en) | 2004-03-10 | 2005-09-22 | Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
US7008783B1 (en) | 1992-09-22 | 2006-03-07 | Maruha Corporation | Gene encoding chondroitinase ABC and uses therefor |
US7074581B2 (en) | 2002-08-09 | 2006-07-11 | Sysmex Corporation | Reagent for assaying lipid |
US7163545B2 (en) | 2002-07-29 | 2007-01-16 | Mayo Foundation For Medical Education And Research | Spinal cord surgical implant |
WO2007038548A2 (en) | 2005-09-26 | 2007-04-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
US20070274979A1 (en) | 2002-05-04 | 2007-11-29 | Gruskin Elliott A | Compositions and Methods for Promoting Neuronal Outgrowth |
US7465705B2 (en) | 2002-08-10 | 2008-12-16 | Yale University | Nogo receptor antagonists |
US7560106B2 (en) * | 1998-08-27 | 2009-07-14 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II and methods of sequencing therewith |
-
2005
- 2005-05-18 EP EP05749189A patent/EP1750757B1/en not_active Not-in-force
- 2005-05-18 US US11/568,831 patent/US8226941B2/en active Active
- 2005-05-18 WO PCT/US2005/017464 patent/WO2005112986A2/en active Application Filing
- 2005-05-18 AU AU2005244933A patent/AU2005244933B2/en not_active Ceased
- 2005-05-18 CA CA2566731A patent/CA2566731C/en not_active Expired - Fee Related
- 2005-05-18 JP JP2007527425A patent/JP4926962B2/ja not_active Expired - Fee Related
- 2005-05-18 ES ES05749189T patent/ES2411504T3/es active Active
- 2005-05-18 MX MXPA06013345A patent/MXPA06013345A/es active IP Right Grant
-
2006
- 2006-11-17 MX MX2011004013A patent/MX341243B/es unknown
Patent Citations (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01500308A (ja) | 1986-07-17 | 1989-02-02 | ヒユーズ・エアクラフト・カンパニー | 軌道上の回転体の姿勢の制御方法 |
US5270194A (en) * | 1989-08-31 | 1993-12-14 | Instrumentation Laboratory Spa | Stabilized glucose oxidase from Aspergillus Niger |
WO1991006303A1 (en) | 1989-10-27 | 1991-05-16 | Case Western Reserve University | Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans |
US5652122A (en) | 1989-12-21 | 1997-07-29 | Frankel; Alan | Nucleic acids encoding and methods of making tat-derived transport polypeptides |
US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5674980A (en) | 1989-12-21 | 1997-10-07 | Biogen Inc | Fusion protein comprising tat-derived transport moiety |
US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
US6184023B1 (en) * | 1992-06-26 | 2001-02-06 | Seikgaka Corporation | Chondroitinase, process for preparing the same, and pharmaceutical composition comprising the same |
US5496718A (en) | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
US5763205A (en) | 1992-06-26 | 1998-06-09 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Producing pure chondroitinase ABC from Proteus vulgaris ATCC 6896 |
JPH06153947A (ja) | 1992-06-26 | 1994-06-03 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼabc、その製造法及び医薬組成物 |
US7008783B1 (en) | 1992-09-22 | 2006-03-07 | Maruha Corporation | Gene encoding chondroitinase ABC and uses therefor |
US5578480A (en) | 1993-04-23 | 1996-11-26 | American Cyanamid Company | Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris |
WO1994025567A1 (en) | 1993-04-23 | 1994-11-10 | American Cyanamid Company | CLONING AND EXPRESSION OF THE CHONDROITINASE I AND II GENES FROM $i(P. VULGARIS) |
US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
WO1995013091A1 (en) | 1993-11-12 | 1995-05-18 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
US5498536A (en) | 1994-04-22 | 1996-03-12 | American Cyanamid Company | Chondroitinase II from Proteus vulgaris |
EP0704532A2 (en) | 1994-06-10 | 1996-04-03 | United States Surgical Corporation | Recombinant chimeric proteins and methods of use thereof |
US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
US5997863A (en) | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
US5792743A (en) | 1995-04-19 | 1998-08-11 | Acorda Therapeutics | Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule |
US6313265B1 (en) | 1995-07-24 | 2001-11-06 | The Scripps Research Institute | Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use |
US5869301A (en) | 1995-11-02 | 1999-02-09 | Lockhead Martin Energy Research Corporation | Method for the production of dicarboxylic acids |
US6326166B1 (en) | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
JPH10174598A (ja) | 1996-12-18 | 1998-06-30 | Nissho Corp | 生体成分測定用試薬の安定化方法 |
US6200564B1 (en) | 1997-04-11 | 2001-03-13 | J. Thomas Lamont | Pharmaceutical compositions containing chondroitinase and uses therefor |
US6007810A (en) | 1997-05-02 | 1999-12-28 | Seikagaku Corporation | Chondroitinase compositions |
JPH11236336A (ja) | 1997-05-02 | 1999-08-31 | Seikagaku Kogyo Co Ltd | コンドロイチナーゼ組成物 |
US6063378A (en) | 1997-08-22 | 2000-05-16 | Seikagaku Corporation | Therapeutic agent for herniated intervertebral disc |
US6153187A (en) | 1997-09-02 | 2000-11-28 | Insight Strategy & Marketing Ltd. | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
JP2002526028A (ja) | 1997-10-17 | 2002-08-20 | ジェネンテック・インコーポレーテッド | ヒトトール相同体 |
WO1999040787A1 (en) | 1998-02-13 | 1999-08-19 | Medinox, Inc. | Modified pharmacologically active agents and improved therapeutic methods employing same |
JP2002505873A (ja) | 1998-03-13 | 2002-02-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 血管内皮増殖因子2 |
WO1999046368A2 (en) | 1998-03-13 | 1999-09-16 | Biomarin Pharmaceuticals | Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment |
US6171575B1 (en) | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
US7560106B2 (en) * | 1998-08-27 | 2009-07-14 | Massachusetts Institute Of Technology | Rationally designed heparinases derived from heparinase I and II and methods of sequencing therewith |
US20040033221A1 (en) | 1998-10-06 | 2004-02-19 | Koichi Masuda | Method for the treatment of chemonucleolysis |
WO2000062067A1 (en) | 1999-02-28 | 2000-10-19 | Washington University | Novel transduction molecules and methods for using same |
WO2000052149A1 (en) | 1999-03-02 | 2000-09-08 | Insight Strategy & Marketing Ltd. | Introducing a biological material into a patient |
JP2003500016A (ja) | 1999-04-02 | 2003-01-07 | イーライ・リリー・アンド・カンパニー | hOB−BP2h組成物、方法およびその使用 |
WO2000064482A1 (en) | 1999-04-21 | 2000-11-02 | Karolinska Innovations Ab | Nerve cell growth modulators (amphibodies) |
WO2000075319A1 (en) | 1999-06-08 | 2000-12-14 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
WO2001039795A2 (en) | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
WO2002008285A2 (en) | 2000-06-22 | 2002-01-31 | Amgen, Inc. | Il-17 molecules and uses thereof |
WO2002055684A2 (en) | 2001-01-09 | 2002-07-18 | Univ Iowa Res Found | Synthetic proteins containing a protein transduction domain |
WO2002065136A2 (en) | 2001-02-15 | 2002-08-22 | University Of Chicago | Yeast screens for agents affecting protein folding |
WO2002083179A2 (en) | 2001-04-12 | 2002-10-24 | Bioaxone Therapeutique Inc. | Fusion proteins |
WO2003000901A2 (en) | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Nucleic acids encoding protein kinases |
WO2003015612A2 (en) | 2001-08-13 | 2003-02-27 | University Of Florida Research Foundation, Inc. | Materials and methods to promote repair of nerve tissue |
US20030040112A1 (en) | 2001-08-13 | 2003-02-27 | Muir David F. | Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
US20030072749A1 (en) | 2001-08-13 | 2003-04-17 | Muir David F. | Materials and methods for nerve repair |
US6972168B2 (en) | 2001-08-13 | 2005-12-06 | University Of Florida Research Foundation, Incorporated | Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
US20030077258A1 (en) | 2001-08-13 | 2003-04-24 | Muir David F. | Materials and methods for nerve grafting |
WO2003022882A2 (en) | 2001-09-11 | 2003-03-20 | Procorde Gmbh | Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
WO2003031578A2 (en) | 2001-10-09 | 2003-04-17 | Immunex Corporation | Mammalian c-type lectins |
AU2003208466B2 (en) | 2002-03-04 | 2008-10-02 | Cambridge Enterprise Limited | Treatment of central nervous system damage |
US20050118157A1 (en) | 2002-03-04 | 2005-06-02 | Mcmahon Stephen B. | Treatment of central nervous system damage |
WO2003074080A1 (en) | 2002-03-04 | 2003-09-12 | Cambridge University Technical Services Limited | Treatment of central nervous system damage |
US20070274979A1 (en) | 2002-05-04 | 2007-11-29 | Gruskin Elliott A | Compositions and Methods for Promoting Neuronal Outgrowth |
WO2003100031A2 (en) | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
WO2003102160A2 (en) | 2002-06-03 | 2003-12-11 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase b |
US20050233419A1 (en) | 2002-06-03 | 2005-10-20 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from chondroitinase B |
US7163545B2 (en) | 2002-07-29 | 2007-01-16 | Mayo Foundation For Medical Education And Research | Spinal cord surgical implant |
JP2004089191A (ja) | 2002-08-09 | 2004-03-25 | Sysmex Corp | 脂質測定試薬 |
US7074581B2 (en) | 2002-08-09 | 2006-07-11 | Sysmex Corporation | Reagent for assaying lipid |
US7465705B2 (en) | 2002-08-10 | 2008-12-16 | Yale University | Nogo receptor antagonists |
US20060153827A1 (en) | 2002-08-15 | 2006-07-13 | Gruskin Elliott A | Chimeric protein |
WO2004017044A2 (en) | 2002-08-15 | 2004-02-26 | Acorda Therapeutics, Inc. | Chimeric protein |
JP2004113166A (ja) | 2002-09-27 | 2004-04-15 | Mitsui Chemicals Inc | ハロペルオキシダ−ゼ活性の安定化方法 |
WO2004110359A2 (en) | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of cns |
US20040265297A1 (en) | 2003-05-16 | 2004-12-30 | Gruskin Elliott A. | Methods of reducing extravasation of inflammatory cells |
WO2004110360A2 (en) | 2003-05-16 | 2004-12-23 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
US20060233782A1 (en) | 2003-05-16 | 2006-10-19 | Gruskin Elliott A | Proteoglycan degrading mutants for the treatment of CNS |
WO2004103299A2 (en) | 2003-05-16 | 2004-12-02 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of cns injuries |
AU2004241088A1 (en) | 2003-05-16 | 2004-12-02 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of CNS injuries |
EP1646353A2 (en) | 2003-05-16 | 2006-04-19 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of cns |
WO2005087920A2 (en) | 2004-03-10 | 2005-09-22 | Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
US7507570B2 (en) * | 2004-03-10 | 2009-03-24 | Massachusetts Institute Of Technology | Recombinant chondroitinase ABC I and uses thereof |
US20060078959A1 (en) | 2004-03-10 | 2006-04-13 | Massachusetts Institute Of Technology | Recombinant chondroitinase ABC I and uses thereof |
WO2007038548A2 (en) | 2005-09-26 | 2007-04-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
US20070104703A1 (en) | 2005-09-26 | 2007-05-10 | Caggiano Anthony O | Compositions and methods of using chondroitinase ABCI mutants |
Non-Patent Citations (150)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9796970B1 (en) | 2017-04-24 | 2017-10-24 | Advantek Serum Laboratories Ltd. | Production of high purity chondroitinase ABC |
WO2018200290A1 (en) * | 2017-04-24 | 2018-11-01 | Advantek Serum Laboratories Ltd. | Production of high purity chondroitinase abc |
Also Published As
Publication number | Publication date |
---|---|
CA2566731A1 (en) | 2005-12-01 |
EP1750757A2 (en) | 2007-02-14 |
WO2005112986A2 (en) | 2005-12-01 |
EP1750757B1 (en) | 2013-03-13 |
EP1750757A4 (en) | 2010-01-13 |
AU2005244933B2 (en) | 2011-08-04 |
ES2411504T3 (es) | 2013-07-05 |
AU2005244933A1 (en) | 2005-12-01 |
JP2008505661A (ja) | 2008-02-28 |
US20080311642A1 (en) | 2008-12-18 |
WO2005112986A3 (en) | 2009-04-16 |
MXPA06013345A (es) | 2008-10-31 |
JP4926962B2 (ja) | 2012-05-09 |
CA2566731C (en) | 2012-07-24 |
MX341243B (es) | 2016-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8226941B2 (en) | Methods of purifying chondroitinase and stable formulations thereof | |
EP2460881B1 (en) | Proteoglycan degrading mutants for treatment of CNS | |
JP3980657B2 (ja) | コンドロイチナーゼabc、その製造法及び医薬組成物 | |
JP4451898B2 (ja) | コンドロイチナーゼabc含有医薬組成物 | |
AU2007307736C1 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
Bakke et al. | Identification, characterization, and molecular cloning of a novel hyaluronidase, a member of glycosyl hydrolase family 16, from Penicillium spp. | |
AU6149300A (en) | Hyaluronidase from the hirudinaria manillensis, isolation, purification and recombinant method of production | |
AU2006294755B2 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
JP2004515575A (ja) | Fgfアフィニティークロマトグラフィー | |
Tokuyasu et al. | Cloning and expression of chitin deacetylase gene from a Deuteromycete, Colletotrichum lindemuthianum | |
EP3266868B1 (en) | Heparinases obtained from sphingobacterium daejeonense, preparation therefor and application thereof | |
JP5094461B2 (ja) | ヒアルロン酸加水分解酵素をコードする遺伝子 | |
WO2012028945A2 (en) | Mutants of l-asparagine | |
US20230091945A1 (en) | Chondroitinase abc mutants and methods of manufacture and use thereof | |
Guo et al. | Expression of a novel hyaluronidase from Streptococcus zooepidemicus in Escherichia coli and its application for the preparation of HA oligosaccharides | |
CN111394344B (zh) | 一种低温耐硫酸盐的透明质酸裂解酶ynlx-hyl及其应用 | |
AU2014200000B2 (en) | Compositions and methods of using chondroitinase abci mutants | |
JPH10182482A (ja) | ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法 | |
CZ20003061A3 (cs) | Farmaceutické přípravky obsahující enzym mikrobiálního původu štěpící kyselinu hyaluronovou |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ACORDA THERAPEUTICS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAGGIANO, ANTHONY O.;GRUSKIN, ELLIOTT A.;SHEPTOVITSKY, YELENA G.;AND OTHERS;REEL/FRAME:019208/0110;SIGNING DATES FROM 20061120 TO 20070205 Owner name: ACORDA THERAPEUTICS, INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CAGGIANO, ANTHONY O.;GRUSKIN, ELLIOTT A.;SHEPTOVITSKY, YELENA G.;AND OTHERS;SIGNING DATES FROM 20061120 TO 20070205;REEL/FRAME:019208/0110 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT, NEW YORK Free format text: SECURITY INTEREST;ASSIGNORS:ACORDA THERAPEUTICS, INC.;CIVITAS THERAPEUTICS, INC.;NEURONEX, INC.;REEL/FRAME:038950/0436 Effective date: 20160601 Owner name: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT Free format text: SECURITY INTEREST;ASSIGNORS:ACORDA THERAPEUTICS, INC.;CIVITAS THERAPEUTICS, INC.;NEURONEX, INC.;REEL/FRAME:038950/0436 Effective date: 20160601 |
|
AS | Assignment |
Owner name: NEURONEX, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:042643/0878 Effective date: 20170504 Owner name: ACORDA THERAPEUTICS, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:042643/0878 Effective date: 20170504 Owner name: CIVITAS THERAPEUTICS, INC., NEW YORK Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT;REEL/FRAME:042643/0878 Effective date: 20170504 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |